MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
May 10, 2023

TRDA's earnings are anticipated to increase 20% to -63 cents per share on May 11.

TRDA, a technology-based company, is scheduled to report its quarterly earnings on May 11. Analysts are expecting a significant rise in earnings, with estimates pointing to a 20% increase, bringing earnings per share (EPS) to -63 cents. The last earnings report on December 31 showed better-than-expected results, with earnings per share of -79 cents, beating the estimate of -83 cents. In this article, we will dive into TRDA's financial ratios and technical indicators to analyze its potential performance after the earnings release.

Sign up for one of these top-performing robots today and start earning more profits in no time!

Key Financial Ratios

  1. Price-to-Book (P/B) Ratio: TRDA's P/B ratio of 1.903 is in line with the industry mean of 23.555, suggesting that the stock is fairly valued relative to its peers.

  2. Price-to-Earnings (P/E) Ratio: The company's P/E ratio of 0.000 is within average values for comparable stocks (124.876), indicating that it is not overpriced based on its earnings.

  3. Projected Growth (PEG Ratio): TRDA's PEG ratio of 0.000 is also within normal values, averaging 3.848, suggesting that the stock's growth prospects are in line with industry standards.

  4. Dividend Yield: The company's dividend yield of 0.000 is around the average of 0.029 among similar stocks, which means that investors can expect a reasonable return on their investment.

  5. Price-to-Sales (P/S) Ratio: TRDA's P/S ratio of 0.000 is also within normal values, averaging 317.511, which implies that the stock is not overvalued based on its sales.

Market Capitalization

With 39.57K shares outstanding, TRDA's current market capitalization sits at $384.64 million. This figure indicates that the company has a reasonable market size, and it has the potential to generate higher revenues in the future.

Technical Analysis

TRDA's 10-day Relative Strength Index (RSI) Indicator recently moved out of the overbought zone on April 18, 2023. This development could signal a shift from an upward trend to a downward trend. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor analyzed 6 instances where the RSI indicator left the overbought zone, and in all cases, the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Although TRDA's financial ratios are within average values, the recent RSI indicator movement suggests that the stock might experience a downward trend in the short term. Investors should closely monitor the company's earnings release on May 11 and consider their investment strategy accordingly. While the company has demonstrated growth in its last earnings report, the technical indicators point towards potential challenges in the near future.

Related Ticker: TRDA

TRDA in upward trend: price rose above 50-day moving average on September 26, 2025

TRDA moved above its 50-day moving average on September 26, 2025 date and that indicates a change from a downward trend to an upward trend. In of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 49 cases where TRDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 10-day moving average for TRDA crossed bullishly above the 50-day moving average on October 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRDA advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 140 cases where TRDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TRDA moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on October 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on TRDA as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TRDA broke above its upper Bollinger Band on October 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.641) is normal, around the industry mean (24.283). P/E Ratio (10.259) is within average values for comparable stocks, (54.634). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.158). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (3.385) is also within normal values, averaging (351.737).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TRDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.03B. The market cap for tickers in the group ranges from 58 to 108.36B. VRTX holds the highest valuation in this group at 108.36B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 62%. RANI experienced the highest price growth at 344%, while LADX experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -32%. For the same stocks of the Industry, the average monthly volume growth was 0% and the average quarterly volume growth was 107%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 82
Price Growth Rating: 54
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
TRDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. TRDA showed earnings on August 06, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
One Design Center Place
Phone
+1 857 520-9158
Employees
159
Web
https://www.entradatx.com
Interact to see
Advertisement
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
#investment#trading
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
#investment#trading
Wall Street expects strong profit growth from the Magnificent Seven tech giants in 2025. Discover how to trade Apple, Microsoft, Amazon, Nvidia, Tesla, Meta, and Alphabet using AI-powered Double Agent strategies and smart hedging with inverse ETFs like QID.
On May 2, 2025, a diverse group of companies across energy, financial services, basic materials, consumer discretionary, and healthcare will release their Q1 2025 earnings.
In April 2025, five tech giants—NVIDIA, Tesla, Meta, Palantir, and Amazon—each surged over 40%, driven by AI breakthroughs, strong earnings, and market momentum. Discover what fueled the rally and how Tickeron’s AI trading bots helped investors outperform even these star stocks.
#investment
Markets ended April with mixed signals—gold slid on trade optimism, Big Tech lifted the Nasdaq, and Bitcoin steadied near $94K. With U.S. GDP contracting and job growth beating forecasts, investors brace for more volatility amid tariffs and central bank moves.
As Warren Buffett announces his retirement, investors turn to his trusted Buffett Indicator—a ratio of market cap to GDP—as a key gauge of market valuation.
#investment
Markets move in repeating cycles—Accumulation, Uptrend, Distribution, and Downtrend. Learn how to recognize each phase and deploy Tickeron’s AI-powered Double Agent strategy to adapt, protect capital, and profit in any market condition.
#trading
Discover how confirmation trading techniques—like moving average crossovers and volume-backed breakouts—can improve accuracy and reduce false signals. Learn how Tickeron’s AI automates these strategies for smarter, faster, and more disciplined trading.
#trading
Hedge funds are ramping up bearish bets on small-cap stocks, with Russell 2000 short interest hitting new highs. As macro headwinds mount and technical support teeters, Tickeron’s AI Double Agents step in to navigate the looming sell-off with precision.
#investment#trading#artificial_intelligence
SPY’s Momentum Indicator turned bullish on April 25, 2025, signaling a potential trend shift with a 90% historical success rate. This article explores how economic scarcity, technical signals, and AI-driven tools like Tickeron’s A.I.dvisor shape investor decisions in volatile markets.
#trading
On May 7, 2025, NVIDIA gained 3.1% on bullish AI momentum and strong data center demand, while Alphabet plunged over 7% amid regulatory fears and growing AI competition—highlighting the tech sector's diverging fortunes in a volatile market.
#investment
A volatile week in financial markets saw the S&P 500 pull back after a record streak, gold surge nearly 5% on Fed jitters, and Bitcoin soar past $104K on trade deal hopes—highlighting the growing impact of policy decisions, earnings, and geopolitical sentiment on asset prices.
ickeron’s AI-powered prediction that Bitcoin would reach $109,000 is nearing reality, as BTC climbs to $103,000. This article explores the accuracy of the forecast, the market forces behind the rally, and how traders can leverage AI tools like Double Agents to stay ahead.
#trading#investment
Monero (XMR) has flashed a bullish signal as its 10-day moving average crosses above the 50-day, historically marking the start of uptrends. With renewed focus on digital privacy and support from Tickeron’s AI agents, XMR may be poised for a quiet breakout.
Tech giants Microsoft, Oracle, Meta, Amazon, and Alphabet (MOMAA) are set to invest a record $320B in AI and cloud infrastructure in 2025—a bold move that could reshape the digital economy. This article explores what’s driving the surge and how investors can respond.
Tickeron’s AI has detected a Rectangle Bottom Bullish pattern in Starbucks (SBUX), signaling a potential short-term rally. With a breakout price of $84.77 and a 63% confidence level, traders are watching closely as AI-driven insights point to a possible upward trend.
#trading
Cisco Systems is set to release its Q3 2025 earnings on May 14, with analysts expecting $0.91 EPS and $14.05B in revenue. This report will test Cisco’s strength in AI and cybersecurity amid networking headwinds. Can Tickeron’s AI Double Agent predict the market reaction?
#investment
U.S. corporate earnings revisions have turned positive for the first time in 2025, signaling renewed analyst confidence. As major firms like Walmart and ExxonMobil report Q1 results, traders look to Tickeron’s AI tools for guidance in a shifting market landscape.
#trading#artificial_intelligence
Enhance your trading with a customizable watchlist that tracks top-performing stocks, ETFs, Forex, and crypto. Set AI-powered Buy/Sell alerts, automate trades with robots, and monitor key performance metrics—all from one streamlined dashboard.
#trading